Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreatic Cancer Resectable

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

radiologically resectable pancreatic cancer patients

Exclusion criteria

a body weight loss of greater than 10% during the six months prior to surgery, the presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal, or heart disease

Treatment and study plan

Gemcitabine

Drug

neoadjuvant therapy for resectable pancreatic cancer using gemcitabine +S1 or gemcitabine + nab-Paxitaxel

Primary outcomes

Investigating the Presence of Occult Metastatic Lesions Detected During Neoadjuvant Therapy.

Time frame: within 6 months

Sponsors and collaborators

Lead sponsor

Kochi University

Other

Registry information

Important dates

Study start: 2015
Primary completion: 2024
Study completion: 2024
First posted: Feb 5, 2025
Registry last updated: Feb 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed